Moderna, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Moderna, Inc. (MRNA) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$2.65 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-20
- Moderna, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$2.65B.
- Moderna, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$3.70B.
- Moderna, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$4.06B, a 143.00% decline from fiscal 2022.
- Moderna, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was $9.43B, a 28.04% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$2.65B 10-K · filed 2026-02-20 | |
| 2024-12-31 | -$3.70B 10-K · filed 2026-02-20 | |
| 2023-12-31 | -$4.06B 10-K · filed 2026-02-20 | |
| 2022-12-31 | $9.43B 10-K · filed 2025-02-21 | |
| 2021-12-31 | $13.11B 10-K · filed 2024-02-23 | |
| 2020-12-31 | -$745.00M 10-K · filed 2023-02-24 | -$745.45M 10-K · filed 2021-02-26 |
| 2019-12-31 | -$509.00M 10-K · filed 2022-02-25 | -$508.60M 10-K · filed 2020-02-27 |
| 2018-12-31 | -$380.47M 10-K · filed 2021-02-26 | |
| 2017-12-31 | -$247.78M 10-K · filed 2020-02-27 | |
| 2016-12-31 | -$211.79M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |